VALIRX PLC LS-001
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stag… Read more
VALIRX PLC LS-001 (EAJF) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, VALIRX PLC LS-001 (EAJF) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
VALIRX PLC LS-001 - Net Assets Trend (None–None)
This chart illustrates how VALIRX PLC LS-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for VALIRX PLC LS-001 (None–None)
The table below shows the annual net assets of VALIRX PLC LS-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to VALIRX PLC LS-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
VALIRX PLC LS-001 Competitors by Market Cap
The table below lists competitors of VALIRX PLC LS-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MONADELPHOUS GRP (8MP.SG)
STU:8MP
|
$166.43K |
|
Ocean Spray Cranberries Inc. PFD 4%
PINK:OCESP
|
$166.44K |
|
Dongsuh Cos. Inc.
KQ:026960
|
$166.51K |
|
SLM (SM1.SG)
STU:SM1
|
$166.62K |
|
SMARTCENTRES REIT V.VTG
F:C7J1
|
$166.34K |
|
MBI Administradora General De Fondo - MBI Deuda Alternativa Fondo De Inversion
SN:CFIMBIDA-A
|
$166.32K |
|
MEDIOBANCA
BE:ME9
|
$166.27K |
|
Fidelity Global Balanced Portfolio
TO:FMPB
|
$166.24K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in VALIRX PLC LS-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares VALIRX PLC LS-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently VALIRX PLC LS-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares VALIRX PLC LS-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| VALIRX PLC LS-001 (EAJF) | €- | N/A | N/A | $166.43K |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |